Begin typing your search above and press return to search.
EPUB Before Print

FULL TEXT

ARTICLE
Therapeutic Plasma Exchange for Management of Early Allograft Dysfunction After Living Donor Liver Transplant: An Unmatched Cohort Study

Abstract

Objectives: Therapeutic plasma exchange has been reported to be useful in the management of acute liver failure and acute-on-chronic liver failure. This retrospective study evaluated therapeutic plasma exchange as an adjunct to standard supportive care for early allograft dysfunction after living donor liver transplant.
Materials and Methods: All consecutive adult living donor liver transplants performed from January 2015 to February 2019 were included. Patients treated without or with therapeutic plasma exchange for early allograft dysfunction (Olthoff criteria) were compared.
Results: There were 465 adult transplant recipients, and 67 (14.4%) had early allograft dysfunction, of which 43 (64%) had therapeutic plasma exchange and 24 (36%) did not. Fourteen patients were excluded, as they had both preoperative and immediate postoperative therapeutic plasma exchange (5 patients with acute liver failure and 9 with acute-on-chronic liver failure). The therapeutic plasma exchange group (n = 29) had more preoperative acute kidney injury (55.2% vs 25.0%; P = .009), lower graft-recipient weight ratio (0.96 vs 1.09; P = .043), and slightly higher final portal pressure (11 vs 10 mg/dL; P = .027). Therapeutic plasma exchange was started at a median of postoperative day 9, with median serum bilirubin of 13.6 mg/dL and a median of 3 sessions per patient. There was no 90-day mortality in the group without therapeutic plasma exchange; however, in the therapeutic plasma exchange group, 13 patients (45%) died (P < .001). Patients who received therapeutic plasma exchange had more septic complications (62.1% vs 12.5%; P < .001) and needed more postoperative renal replacement therapy (51.7% vs 8.3%; P < .001).
Conclusions: This is the first study to compare patients treated with or without therapeutic plasma exchange for early allograft dysfunction in the living donor liver transplant setting. Within the limitations of this retrospective study, we were unable to confirm whether therapeutic plasma exchange could increase early mortality.


Key words : Graft dysfunction, Plasmapheresis, Total plasma exchange

Introduction

Early allograft dysfunction (EAD) after living donor liver transplant (LDLT) has been reported to range from 10% to 25%, and the cause is often multifactorial.1,2 Common risk factors for EAD in the LDLT setting are poor preoperative recipient condition, such as a high Model for End-Stage Liver Disease (MELD) score, need for preoperative organ support, older donor age, higher donor body mass index (BMI, calculated as weight in kilograms divided by height in meters squared), low graft-recipient weight ratio (GRWR), left-lobe grafts, and higher portal perfusion pressure leading to graft injury and posttransplant sepsis.2 If these patients are supported during the period of graft dysfunction, most would recover without any long-term consequences.3 However, despite advances in care of patients after liver transplant, there remains a high risk of early liver graft loss after EAD of up to 24% in the first 90 days.3

Therapeutic plasma exchange (TPE) has been reported to be beneficial in the management of acute liver failure and acute-on-chronic liver failure.4,5 Therapeutic plasma exchange can theoretically improve the milieu around the graft liver and thereby enhance regeneration, improve coagulation profile, and avoid cerebral edema.6 The beneficial role of plasma exchange is the clearance of ammonia, inflammatory cytokines, and markers of oxidative stress, as well as amelioration of dysregulated immune system.7,8 There have been reports of TPE use in the deceased donor liver transplant (DDLT) setting, where it has led to improvement in EAD in a few cases of primary nonfunction.9-12 However, there are also reports that TPE is associated with higher mortality and graft loss in the DDLT setting.13,14

To date, there are only a few reports of TPE use in the LDLT setting (Table 1).15-18 All of these studies have shown higher morbidity and mortality when graft dysfunction occurs in the setting of LDLT. Except for a single study,17 all others have reported beneficial effects of TPE to overcome the ill effects of EAD.15,16,18 We have used TPE as an adjunct to standard supportive therapy for EAD after LDLT since 2015. The aim of the current study was to evaluate our practice of using TPE in the management of EAD after LDLT.

Materials and Methods

Local trust board ethics approval was obtained for this study. Data were retrieved from a prospectively maintained institutional liver transplant database. All consecutive adult LDLTs (all were first-degree or second-degree related donors) performed between January 2015 and February 2019 (50 months) were included.

Data included recipient demographics, etiology of liver disease, preoperative comorbidities including diabetes mellitus, hypertension and coronary artery disease, MELD score, preoperative status at the time of transplant, preoperative acute kidney injury (AKI: creatinine >1.6 mg/dL) or sepsis within 4 weeks, preoperative liver function tests, and donor demographics. Intraoperative factors included graft type, graft weight, GRWR, anterior sector reconstruction, final portal pressure, portal flow modulation, cold ischemia time, intraoperative blood loss, intraoperative blood product requirements, duration of surgery, and need for more for than 1 inotrope for >30 minutes intraoperatively. Postop­erative outcomes included technical and infective complications, need for organ support, duration of ventilation, intensive care unit (ICU) readmission, lengths of ICU and hospital stays, and 30-day and 1-year survival rates.

Early allograft dysfunction was defined by the Olthoff criteria as the presence of 1 or more of the following: day 7 bilirubin ≥10 mg/dL or interna­tional normalized ratio (INR) ≥1.6, or alanine aminotransferase or aspartate aminotransferase >2000 IU/L within the first 7 days.19 Patients who had EAD were identified from the database, and patients who received TPE along with standard supportive treatment were compared with those who did not have TPE during the study period. For those who had TPE, the number of TPE sessions, the postoperative days when TPE started and ended, and any TPE-related or transfusion-related adverse events were noted. Primary outcomes for the study were 30-day and 1-year survival rates. Secondary outcomes included grade III or higher Clavien-Dindo complications and lengths of ICU and hospital stays.

Details of therapeutic plasma exchange
Decisions regarding initiation and continuation of TPE were individualized and planned during daily multidisciplinary meetings. Patients with EAD and evidence of nonhepatic organ dysfunction with systemic inflammatory response syndrome were considered for TPE. Further sessions were based on trend in liver function tests and the clinical condition of the patient. Therapeutic plasma exchange was terminated when there was consistent clinical improvement or severe deterioration considered to be futile.

The Spectra Optia therapeutic apheresis system (Terumo BCT) with centrifugal technology was used for TPE. In all TPE procedures, acid citrate dextrose A anticoagulation with the inlet-to-anticoagulant ratio between 1:12 and 1:15 and dual vascular access were used. Patient total blood volume (BV) was calculated by the Nadler formula, and plasma volume (PV) was calculated according to the formula PV  =  BV × (1  −  hematocrit).20 Low-volume plasma exchange was performed, in which 1 to 1.5 plasma volumes per session were replaced with saline, albumin, and/or fresh-frozen plasma.

Statistical analyses
Categorical variables are expressed as the frequencies and proportions (%), and continuous variables are presented as median values with interquartile ranges (IQR). Categorical variables were analyzed by the Fisher exact test or the chi-square test and continuous variables by the nonparametric Mann-Whitney U test. For all analyses, we compared 2 groups: the TPE group and the group without TPE. P < .05 was considered statistically significant. Multivariate logistic regression analysis was performed to identify factors that predicted the use of TPE for EAD. Kaplan-Meier survival curves were studied with log-rank statistics to assess the patient survival. Cox regression analyses were performed to identify the independent predictors of survival. A receiver operating curve (ROC) analysis was used to identify the cutoff value of the number of TPE sessions that was predictive of treatment success. Based on the area under the ROC (AUC), the sensitivity and specificity of the number of TPE sessions was identified. All statistical analyses were performed with SPSS software (version 26.0).

Results

Over the 50-month study period, 659 LDLTs were performed, of which 465 (70.6%) were adult trans­plants and 194 (29.4%) were pediatric transplants. Sixty-seven adult patients (14.4%) had EAD, of which 43 had TPE and 24 had no TPE. Fourteen of these 43 patients had TPE before or in the immediate period after transplant; hence, these patients were excluded from the study. Five of these preoperative or early TPEs were for acute liver failure and 9 were for acute-on-chronic liver failure.

Twenty-nine patients who had TPE for EAD based on Olthoff criteria were included in the study and compared with the 24 who did not have TPE. There was no difference in pretransplant bilirubin levels between patients with and without TPE (median of 4.4 [IQR, 2.3-18.0] mg/dL vs 4.2 [IQR, 2.4-10.7] mg/dL, respectively; P = .538). Early allograft dysfunction was defined for the TPE group based on day 7 bilirubin >10 mg/dL in 24 patients (82.7%) and day 7 INR >1.6 in 5 patients (17.3%). In the group without TPE, 23 patients (95.8%) fit the EAD definition based on day 7 bilirubin and 1 patient (4.2%) fit the definition based on day 7 INR.

Preoperative and intraoperative factors between groups with and without therapeutic plasma exchange
There was no difference between the 2 treatment groups in terms of recipient age, but there were more male patients in the TPE group (82.8% vs 54.2%; P = .024) and the TPE recipients had higher BMI (median 26 vs 23; P = .006). There was no difference between the 2 groups in terms of etiology of liver disease, pretransplant comorbidities, MELD score, and pretransplant bilirubin. However, more patients in the TPE group had AKI before transplant (55.2% vs 25.0%; P = .009), but there was no difference in need for pretransplant renal support (Table 2). Similarly, there was no difference between the 2 groups in terms of donor demographics, including donor liver attenuation index. There was no difference between the 2 groups in terms of type of graft, anterior sector reconstruction for right-lobe graft, and need for portal flow modulation; however, the median GRWR was slightly lower (0.96 vs 1.09; P = .043) and final portal pressure was slightly higher in the group with TPE (median, 11 vs 10 mm Hg; P = .027) than in the group without TPE. There was no difference between the 2 groups in terms of cold ischemia time, intraoperative blood loss, blood product requirements, and duration of surgery (Table 3).

Therapeutic plasma exchange sessions and biochemical parameters
Therapeutic plasma exchange was started at a median of 9 days postoperatively (IQR, 7-19 days) and the final TPE session was a median of 13 days postoperatively (IQR, 7-41 days). The median number of TPE sessions was 3 (IQR, 7-11). There was only 1 patient who had mild urticaria after the first TPE session; otherwise there were no other adverse events of TPE. The change in liver function tests from the first to the last TPE session is tabulated in Table 4. There was no statistical difference between the liver function tests from the first to the last TPE.

Postoperative outcomes for the groups with and without therapeutic plasma exchange
Consistent with the higher rate of preoperative AKI, more patients in the TPE group needed posttransplant renal replacement (51.7% vs 8.3%; P < .001). There was no difference in vascular or biliary complications between the 2 groups, but the septic complications were significantly higher in the TPE group (62.1% vs 12.5%; P < .001). Although the posttransplant sepsis rate was high in the TPE group, most of the septic episodes were before the first TPE session (n = 9; range, 2-6 days before TPE start) and few were after TPE (n = 5; range, 3-8 days after the first TPE session) (Table 5).

More patients in the TPE group needed ICU readmission (37.9% vs 16.7%), but this was not statistically significant (P = .087). Grade III and higher Clavien-Dindo complications were more common in the TPE group, mostly from the higher rate of 30-day mortality. Eleven patients (38%) died within 30 days and 2 other patients died within 90 days in the TPE group, for a total of 13 (45%), all caused by sepsis and multiorgan failure along with EAD (P < .001). There were no deaths in the group without TPE. The median ICU stay was longer in the TPE group (13.5 vs 6.0 days; P < .001), but there was no significant difference in length of hospital stay (33.5 vs 24.5 days; P = .093). The 90-day mortality rate for all EAD patients in our cohort was 24.5%. The 1-year and 3-year survival rates were 55% and 45% for the TPE cohort and 95% and 90% for cohort without TPE, respectively (Table 5, Figure 1). Our 1-year and 3-year survival rates for the whole cohort (465 patients) during the studied period were 94% and 89%, respectively.

Predictors of need for therapeutic plasma exchange and comparison of survivors and nonsurvivors in the therapeutic plasma exchange cohort
Multivariate analysis showed that the following factors predicted the need for TPE: recipient BMI >25 (odds ratio, 1.38; 95% CI, 1.07-1.77; P = .013), pretransplant AKI (odds ratio, 0.06; 95% CI, 0.01-0.51; P = .011), and final portal pressure >10 mm Hg (odds ratio, 1.87; 95% CI, 1.18-2.97; P = .008) (Table 6).

The nonsurvivors (n = 14) needed more TPE sessions (median, 3.5; IQR, 2-6) than did the survivors (n = 15) (median, 2; IQR, 1-4), but this difference was not statistically significant. The day 7 bilirubin (median, 15 vs 11 mg/dL; P = .172), the postoperative day when TPE started (median, 9 vs 9.5 days; P = .652), and the postoperative day when TPE ended (median, 11 vs 15 days; P = .172) were not different between survivors and nonsurvivors, respectively. However, postoperative AKI (93% vs 47%; P = .007) and need for dialysis (86% vs 20%; P < 0001) were significantly higher in those who did not survive. The survivors and the nonsurvivors in the TPE group were subjected to univariate analysis, which showed that non-right-lobe graft (P = .042) and no anterior sector reconstruction for right-lobe graft (P = .045) were poor prognosticators on univariate analysis. On multivariate analysis, only the use of non-right-lobe graft (hazard ratio, 3.50; 95% CI, 0.94-45.10; P = .058) predicted worse outcomes (Table 7). We had 2 right posterior graft recipients and 2 left-lobe graft recipients in our TPE cohort, all of whom died within 30 days of transplant. On ROC analysis, the need for 4 or more sessions of TPE was a predictor for failure of treatment and for mortality (AUC, 0.590; sensitivity, 65%; specificity, 55%) (Figure 2).

Outcomes from the excluded cohort (n = 14)
The 5 acute liver failure and 9 acute-on-chronic liver failure patients who were excluded because of both pretransplant and immediate posttransplant TPE had a median pre-TPE bilirubin level of 15 mg/dL (IQR, 10-32 mg/dL). The median number of TPE sessions in this cohort was 4 mg/dL (IQR, 2-18 mg/dL). Five patients died within 90 days in this cohort (35.7%), all from septic complications.

Discussion

This is the first study to compare the outcomes of TPE with no TPE for EAD in the LDLT setting alone. The use of therapeutic plasma exchange for EAD after LDLT in our cohort did not show clear survival benefits, and it is unclear whether this treatment is associated with higher mortality. Early allograft dysfunction associated with posttransplant sepsis and the need for renal support are significant risk factors for mortality. In our study, we found that that no improvement of graft function after 3 sessions of TPE predicted mortality.

The largest report of TPE use in EAD compared 107 TPE patients with 36 patients without TPE; however, 66% were LDLTs and 34% were DDLTs. The investi­gators performed an average of 10 sessions of TPE for any recipient who had bilirubin >10 mg/dL on 3 consecutive days, which is not a standard accepted definition for EAD. They patient cohort with TPE had much better 30-day and 1-year survival (82% and 54%) compared with the cohort without TPE (58% and 22%, respectively).15 Other studies that reported on the use of TPE for EAD in LDLT did not compare results with patients without TPE or did not use a standard definition for EAD (Table 1).16-18

All the early deaths in our study were in the TPE group; however, this finding did not implicate TPE as the cause for higher sepsis and increased mortality. Of note, TPE patients were much sicker and had greater incidence of pretransplant AKI (55.2% vs 25.0%; P = .009) and sepsis (37.9% vs 16.7%; P = .087) compared with patients without TPE. Previous studies have shown that pretransplant renal issues and sepsis may lead to worse outcomes after transplant.21,22

Plasma exchange has the potential to improve survival in sepsis by removal of inflammatory cytokines and restoration of deficient plasma proteins.23,24 However, the efficacy of plasma exchange as a treatment strategy for sepsis and septic shock was refuted by a meta-analysis of 194 patients and subsequently by a Cochrane review of 200 high-volume hemodiafiltration patients that suggested low-quality studies and no overall benefit compared with standard treatment.25,26 One of the problems of plasma exchange is nonselective removal of substances from the blood, including antibiotics and immunosuppression agents that are crucial for the management of posttransplant sepsis.27 The amount of a particular substance removed during TPE is determined by factors related to the plasma exchange procedure such as volume of exchange, duration of procedure, and the frequency of TPE.28 Therefore, our protocols of using low-volume exchange, restricting the duration of the TPE procedure to 2 to 3 hours, and adjusting the timing/dose of antibiotics and immunosuppressants are important aspects for consideration. With its known benefits in antibody-mediated rejection, we found that none of our TPE patients had rejection before the first discharge from hospital compared with 4 in the group without TPE, all of which responded to pulse steroids (P = .036).

From our series, we identified that recovery of liver function after TPE was characterized by the ability to maintain low bilirubin, whereas progressive liver failure was associated with worse levels of bilirubin. Therefore, clinical correlation is imperative, and hence a protocol to perform a definite number of TPE sessions may not be advisable. Although our study had a small number of patients, we suggest that the daily trend in bilirubin and enzyme levels should guide further sessions, rather than a large number of consecutive sessions that may not be needed and may actually increase the risk of line-related and other transfusion-related complications.

Liver graft dysfunction along with the need for renal support are 2 of the most difficult conditions to manage in a posttransplant patient and may lead to a vicious cycle and no improvements despite the best intensive care management. Both of these conditions add to increased risk of early bacteremia (AUC, 0.707; P < .001), with was shown in a study of 610 LDLTs. That study also showed that EAD significantly correlated with nonresolving infection (correlation coefficient, 0.305; P < .05).29 Posttransplant EAD has been independently associated with renal nonrecovery in liver transplant recipients who are on renal replacement therapy for a short duration pretransplant. Furthermore, EAD in the setting of renal nonrecovery also resulted in the worst survival outcomes.30 Together, these findings could have led to the high mortality shown in our TPE cohort.

The major strength of our study is that we used a standard definition of EAD to compare outcomes between the TPE group and group without TPE, which added to the robustness of the assessment and provided a meaningful comparison of outcomes between the 2 different management options. Such comparisons with recipients who did not receive TPE are lacking in most published studies on this topic; in addition, the lack of standard criteria disallowed a comparison of outcomes between studies.

Conclusions

Therapeutic plasma exchange may provide effective liver support for EAD patients, but the associated renal dysfunction and sepsis may increase mortality in these high-risk patients. There is need for randomized studies to further evaluate the role of TPE in post-LDLT EAD.


References:


  1. Graham JA, Samstein B, Emond JC. Early graft dysfunction in living donor liver transplantation and the small for size syndrome. Curr Transplant Rep. 2014;1(1):43-52. doi:10.1007/s40472-013-0006-1
    CrossRef - PubMed
  2. Chae MS, Kim Y, Lee N, et al. Graft regeneration and functional recovery in patients with early allograft dysfunction after living-donor liver transplantation. Ann Transplant. 2018;23:481-490. doi:10.12659/AOT.909112
    CrossRef - PubMed
  3. Pomposelli JJ, Goodrich NP, Emond JC, et al. Patterns of early allograft dysfunction in adult live donor liver transplantation: the A2ALL experience. Transplantation. 2016;100(7):1490-1499. doi:10.1097/TP.0000000000001240
    CrossRef - PubMed
  4. Tan EX, Wang MX, Pang J, Lee GH. Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review. World J Gastroenterol. 2020;26(2):219-245. doi:10.3748/wjg.v26.i2.219
    CrossRef - PubMed
  5. Stahl K, Hadem J, Schneider A, et al. Therapeutic plasma exchange in acute liver failure. J Clin Apher. 2019;34(5):589-597. doi:10.1002/jca.21737
    CrossRef - PubMed
  6. Kaplan AA. Therapeutic plasma exchange: a technical and operational review. J Clin Apher. 2013;28(1):3-10. doi:10.1002/jca.21257
    CrossRef - PubMed
  7. Maiwall R, Moreau R. Plasma exchange for acute on chronic liver failure: is there a light at the end of the tunnel? Hepatol Int. 2016;10(3):387-389. doi:10.1007/s12072-016-9703-z
    CrossRef - PubMed
  8. Maheshwari A, Bajpai M, Patidar GK. Effects of therapeutic plasma exchange on liver function test and coagulation parameters in acute liver failure patients. Hematol Transfus Cell Ther. 2020;42(2):125-128. doi:10.1016/j.htct.2019.05.003
    CrossRef - PubMed
  9. Camci C, Akdogan M, Gurakar A, et al. The impact of total plasma exchange on early allograft dysfunction. Transplant Proc. 2004;36(9):2567-2569. doi:10.1016/j.transproceed.2004.09.071
    CrossRef - PubMed
  10. Mandal AK, King KE, Humphreys SL, Maley WR, Burdick JF, Klein AS. Plasmapheresis: an effective therapy for primary allograft nonfunction after liver transplantation. Transplantation. 2000;70(1):216-220.
    CrossRef - PubMed
  11. Rammohan A, Sachan D, Logidasan S, Sathyanesan J, Palaniappan R, Rela M. Role of plasmapheresis in early allograft dysfunction following deceased donor liver transplantation. World J Hematol. 2017;6(1):24-27. doi:10.5315/wjh.v6.i1.24
    CrossRef - PubMed
  12. Lee JY, Kim SB, Chang JW, et al. Comparison of the molecular adsorbent recirculating system and plasmapheresis for patients with graft dysfunction after liver transplantation. Transplant Proc. 2010;42(7):2625-2630. doi:10.1016/j.transproceed.2010.04.070
    CrossRef - PubMed
  13. Salvalaggio PR, Felga GE, Afonso RC, Ferraz-Neto BH. Early allograft dysfunction and liver transplant outcomes: a single center retrospective study. Transplant Proc. 2012;44(8):2449-2451. doi:10.1016/j.transproceed.2012.08.002
    CrossRef - PubMed
  14. Skerrett D, Mor E, Curtiss S, Mohandas K. Plasmapheresis in primary dysfunction of hepatic transplants. J Clin Apher. 1996;11(1):10-13. doi:10.1002/(SICI)1098-1101(1996)11:1<10::AID-JCA2>3.0.CO;2-E
    CrossRef - PubMed
  15. Choe W, Kwon SW, Kim SS, Hwang S, Song GW, Lee SG. Effects of therapeutic plasma exchange on early allograft dysfunction after liver transplantation. J Clin Apher. 2017;32(3):147-153. doi:10.1002/jca.21472
    CrossRef - PubMed
  16. Yamamoto R, Nagasawa Y, Marubashi S, et al. Early plasma exchange for progressive liver failure in recipients of adult-to-adult living-related liver transplants. Blood Purif. 2009;28(1):40-46. doi:10.1159/000210036
    CrossRef - PubMed
  17. Kozaki K, Fukatsu A, Kasahara M, Ogura Y, Egawa H, Tanaka K. The role of apheresis therapy in living donor liver transplantation. Ther Apher Dial. 2004;8(3):174-179. doi:10.1111/j.1526-0968.2004.00133.x
    CrossRef - PubMed
  18. Park CS, Hwang S, Park HW, et al. Role of plasmapheresis as liver support for early graft dysfunction following adult living donor liver transplantation. Transplant Proc. 2012;44(3):749-751. doi:10.1016/j.transproceed.2012.01.054
    CrossRef - PubMed
  19. Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949. doi:10.1002/lt.22091
    CrossRef - PubMed
  20. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51(2):224-232.
    CrossRef - PubMed
  21. Weber ML, Ibrahim HN, Lake JR. Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl. 2012;18(11):1290-1301. doi:10.1002/lt.23522
    CrossRef - PubMed
  22. Park MH, Shim HS, Kim WH, et al. Clinical risk scoring models for prediction of acute kidney injury after living donor liver transplantation: a retrospective observational study. PLoS One. 2015;10(8):e0136230. doi:10.1371/journal.pone.0136230
    CrossRef - PubMed
  23. David S, Stahl K. To remove and replace: a role for plasma exchange in counterbalancing the host response in sepsis. Crit Care. 2019;23(1):14. doi:10.1186/s13054-018-2289-1
    CrossRef - PubMed
  24. Knaup H, Stahl K, Schmidt BMW, et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care. 2018;22(1):285. doi:10.1186/s13054-018-2220-9
    CrossRef - PubMed
  25. Rimmer E, Houston BL, Kumar A, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care. 2014;18(6):699. doi:10.1186/s13054-014-0699-2
    CrossRef - PubMed
  26. Borthwick EM, Hill CJ, Rabindranath KS, Maxwell AP, McAuley DF, Blackwood B. High?volume haemofiltration for sepsis in adults. Cochrane Database Syst Rev. 2017;1(1):CD008075. doi:10.1002/14651858.CD008075.pub3
    CrossRef - PubMed
  27. Cheng CW, Hendrickson JE, Tormey CA, Sidhu D. Therapeutic plasma exchange and its impact on drug levels: an ACLPS critical review. Am J Clin Pathol. 2017;148(3):190-198. doi:10.1093/ajcp/aqx056
    CrossRef - PubMed
  28. Ibrahim RB, Balogun RA. Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose. Semin Dial. 2012;25(2):176-189. doi:10.1111/j.1525-139X.2011.01030.x
    CrossRef - PubMed
  29. Park J, Kim BW, Choi HJ, et al. Risk stratification for early bacteremia after living donor liver transplantation: a retrospective observational cohort study. BMC Surg. 2020;20(1):2. doi:10.1186/s12893-019-0658-6
    CrossRef - PubMed
  30. Wadei HM, Lee DD, Croome KP, et al. Early allograft dysfunction is associated with higher risk of renal nonrecovery after liver transplantation. Transplant Direct. 2018;4(4):e352. doi:10.1097/TXD.0000000000000771
    CrossRef - PubMed


DOI : 10.6002/ect.2021.0064


PDF VIEW [197] KB.

From the Institute of Liver Disease & Transplantation, Dr. Rela Institute & Medical Centre, and the Bharath Institute of Higher Education & Research, Chennai, India
Acknowledgements: The authors have not received any funding or grants in support of the presented research or for the preparation of this work and have no declarations of potential conflicts of interest.
Author contributions: ARH and MSR planned and designed the study. JS and SS collected the data required for the study. DS was the transfusion medicine specialist involved in the therapeutic plasma exchange procedures for the patients. ARH performed the statistical analyses and wrote the manuscript. DS, DJ, AR, MSR, and MR reviewed and revised the manuscript.
Corresponding author: Professor Mohamed Rela, Dr. Rela Institute & Medical Centre, No. 7, CLC Works Road, Chromepet, Chennai, Tamil Nadu 600 044, India
Phone: +91 44 6666 7788
E-mail: mohamedrela@gmail.com